11 04 2016Metabomed completed an $18 million extension of Series A financing round
HFN advised MS Ventures, the corporate venture capital arm of Merck Serono, in its investment in an Israeli cancer metabolism company Metabomed. Metabomed has completed an $18 million extension of Series A financing round.
In addition to MS Ventures, investors include Boehringer Ingelheim Venture Fund, Pontifax Fund, and the Technion Research and Development Foundation. New investors, Pfizer and Arkin Holdings also joined the round.
MS Ventures is the strategic, corporate venture arm of the biopharmaceutical division of Merck KGaA, Darmstadt, Germany. We invest globally in emerging biotechnology companies that develop products and or technologies that have the potential to significantly improve patient outcomes.
Along with the â‚¬100 million MS Ventures fund, our team also manages the â‚¬30 million Entrepreneur Partnership Program fund established to support the creation of spin-offs and the â‚¬ 10 million Israel Bioincubator Fund, focused on pre-seed and seed opportunities coming out of Israel.
Â Hi-Tech HFN' Partner Dan Sharot (Picture) led the transaction. Involved fees earner: Dan Sharot - Herzog Fox & Neeman;
see all videos
Hong Kong has become a city of bright expansion, culture, and futuristic innovation. Fr
Fintech, it’s described as the disruption in financial services pushed by consume
On October 14th, 2016, the world’s leading corporate stars aligned for a momentou
More than 19 Excellences in the global economy at the VI Annual Edition of IAIR AWARDS&
It took place on 19 November 2015 at Palace Downtown in Dubai the 19th edition of the I